Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells
Wu, Lei, Adams, Mary, Carter, Troy, Chen, Roger, Muller, George, Stirling, David, Schafer, Peter, Bartlett, J Blake
Published in Clinical cancer research (15.07.2008)
Published in Clinical cancer research (15.07.2008)
Get full text
Journal Article
anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Galustian, Christine, Meyer, Brendan, Labarthe, Marie-Christine, Dredge, Keith, Klaschka, Deborah, Henry, Jake, Todryk, Stephen, Chen, Roger, Muller, George, Stirling, David, Schafer, Peter, Bartlett, J. Blake, Dalgleish, Angus G
Published in Cancer Immunology, Immunotherapy (01.07.2009)
Published in Cancer Immunology, Immunotherapy (01.07.2009)
Get full text
Journal Article
The evolution of thalidomide and its IMiD derivatives as anticancer agents
Bartlett, J. Blake, Dredge, Keith, Dalgleish, Angus G
Published in Nature reviews. Cancer (01.04.2004)
Published in Nature reviews. Cancer (01.04.2004)
Get full text
Journal Article
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Sborov, Douglas W., Baljevic, Muhamed, Reeves, Brandi, Laubach, Jacob, Efebera, Yvonne A., Rodriguez, Cesar, Costa, Luciano J., Chari, Ajai, Silbermann, Rebecca, Holstein, Sarah A., Anderson, Larry D., Kaufman, Jonathan L., Shah, Nina, Pei, Huiling, Patel, Sharmila, Cortoos, Annelore, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Voorhees, Peter M., Richardson, Paul G.
Published in British journal of haematology (01.11.2022)
Published in British journal of haematology (01.11.2022)
Get full text
Journal Article
Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo
Zhang, Liang, Qian, Zhengzi, Cai, Zhen, Sun, Luhong, Wang, Huaqing, Bartlett, J. Blake, Yi, Qing, Wang, Michael
Published in American journal of hematology (01.09.2009)
Published in American journal of hematology (01.09.2009)
Get full text
Journal Article
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions
Lu, Ling, Payvandi, Faribourz, Wu, Lei, Zhang, Ling-Hua, Hariri, Robert J, Man, Hon-Wah, Chen, Roger S., Muller, George W., Hughes, Christopher C.W., Stirling, David I., Schafer, Peter H., Bartlett, J. Blake
Published in Microvascular research (01.03.2009)
Published in Microvascular research (01.03.2009)
Get full text
Journal Article
Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya, Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Bartlett, J. Blake, Vermeulen, Jessica, Lin, Thomas S., Richardson, Paul G., Voorhees, Peter
Published in Blood cancer journal (New York) (13.04.2022)
Published in Blood cancer journal (New York) (13.04.2022)
Get full text
Journal Article
Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers
Wu, Lei, Parton, Anastasia, Lu, Ling, Adams, Mary, Schafer, Peter, Bartlett, J. Blake
Published in Cancer Immunology, Immunotherapy (01.01.2011)
Published in Cancer Immunology, Immunotherapy (01.01.2011)
Get full text
Journal Article
Relationship between treatment effects on progression-free survival and overall survival in multiple myeloma: a systematic review and meta-analysis of published clinical trial data
Cartier, Shannon, Zhang, Bin, Rosen, Virginia M, Zarotsky, Victoria, Bartlett, J Blake, Mukhopadhyay, Pralay, Wagner, Samuel, Davis, Catherine
Published in Oncology research and treatment (01.03.2015)
Published in Oncology research and treatment (01.03.2015)
Get more information
Journal Article
Daratumumab for patients with myeloma with early or late relapse after initial therapy: subgroup analysis of CASTOR and POLLUX
Spencer, Andrew, Moreau, Philippe, Mateos, Maria-Victoria, Goldschmidt, Hartmut, Suzuki, Kenshi, Levin, Mark-David, Sonneveld, Pieter, Orlowski, Robert Z, Yoon, Sung-Soo, Usmani, Saad Z, Weisel, Katja, Reece, Donna, Ahmadi, Tahamtan, Pei, Huiling, Mayo, Wendy Garvin, Gai, Xue, Carey, Jodi, Bartlett, J Blake, Carson, Robin, Dimopoulos, Meletios A
Published in Blood advances (23.01.2024)
Published in Blood advances (23.01.2024)
Get full text
Journal Article
The synthetic compound CC-5079 is a potent inhibitor of tubulin polymerization and tumor necrosis factor-α production with antitumor activity
ZHANG, Ling-Hua, LEI WU, BARTLETT, J. Blake, SCHAFER, Peter H, PAWANDI, Faribourz, RAYMON, Heather K, CHEN, Roger S, CORRAL, Laura, SHIRLEY, Michael A, NARLA, Rama Krishna, GAMEZ, Jim, MULLER, George W, STIRLING, David I
Published in Cancer research (Chicago, Ill.) (15.01.2006)
Published in Cancer research (Chicago, Ill.) (15.01.2006)
Get full text
Journal Article
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro
Dredge, Keith, Horsfall, Rebecca, Robinson, Simon P., Zhang, Ling-Hua, Lu, Ling, Tang, Yang, Shirley, Michael A., Muller, George, Schafer, Peter, Stirling, David, Dalgleish, Angus G., Bartlett, J. Blake
Published in Microvascular research (2005)
Published in Microvascular research (2005)
Get full text
Journal Article
Thalidomide-derived immunomodulatory drugs as therapeutic agents
Galustian, Christine, Labarthe, Marie-Christine, Bartlett, J Blake, Dalgleish, Angus G
Published in Expert opinion on biological therapy (01.12.2004)
Published in Expert opinion on biological therapy (01.12.2004)
Get more information
Journal Article
P-329 Diagnostic Challenges Across the Multiple Myeloma Pathway: Perspectives of Primary Care Physicians and Orthopedic Specialists
Davies, Faith, Beer, Hayley, Faiman, Beth, Bartlett, J Blake, Attfield, Georgia, Gilbert, Maya, Egbase, Daniel, Mikhael, Joseph
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2024)
Get full text
Journal Article
P-461 An overview of challenges experienced in multiple myeloma: perspectives of hematologist-oncologists and specialist nurses
Davies, Faith, Beer, Hayley, Faiman, Beth, Mikhael, Joseph, Bartlett, J Blake, Attfield, Georgia, Price, Tallulah, Gilbert, Maya
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil C., Paiva, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan M., Jackson, Carolyn C., Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-min, Bartlett, J. Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam D., San-Miguel, Jesús
Published in Blood (15.11.2022)
Published in Blood (15.11.2022)
Get full text
Journal Article
POSTER: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article
Oral Abstract: MM-304 Efficacy Outcomes and Characteristics of Patients With Multiple Myeloma (MM) Who Achieved Sustained Minimal Residual Disease Negativity After Treatment With Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1
Munshi, Nikhil, Pavia, Bruno, Martin, Thomas, Usmani, Saad, Lin, Yi, Schecter, Jordan, Jackson, Carolyn, Madduri, Deepu, Zudaire, Enrique, Yeh, Tzu-Min, Bartlett, J Blake, Pacaud, Lida, Akram, Muhammad, Geng, Dong, Jagannath, Sundar, Cohen, Adam, San-Miguel, Jesús
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Published in Clinical lymphoma, myeloma and leukemia (01.09.2023)
Get full text
Journal Article